Dr. Kimberly Blackwell is Vice President of Early Phase Development and Immuno-oncology at Lilly Oncology. In addition, Kim is Co-Founder of Cereius, a company that aims to improve the lives and survival of patients with solid tumor brain metastasis by using personalized and highly targeted radiotherapy. After 25 years of treating patients and conducting breast cancer research, Kim recently left her position in academic medicine to focus her efforts on getting new drugs to patients facing cancer. Kim’s hobbies include spending time with her family, watching her son’s baseball games, practicing yoga, meditating, skiing, and horseback riding. Kim received her bachelor’s degree in bioethics from Duke University and her M.D. from Mayo Clinic Medical School. Afterwards, she completed an internship and residency in internal medicine, as well as a fellowship in hematology/oncology at Duke University Medical School. Prior to accepting her position at Lilly, Kim was a faculty member at Duke University Medical Center. Kim has received numerous awards and honors throughout her career, including the Duke University Distinguished Alumni Award, the Young Investigator Award in Breast Cancer from the National Cancer Institute Specialized Program of Research Excellence, and the Joseph Greenfield Award for Mentorship of Clinical Research. She was also recognized as one of TIME Magazine's 100 Most Influential People in the World in 2013. In our interview Kim shares more about her life and science.
People Behind the Science Podcast Stories from Scientists about Science, Life, Research, and Science Careers